Skip to main content
Top
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Commentary

The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages

Author: J Robert Coleman

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

With the prospect of another pandemic Influenza fresh in our consciousness, the pathogenic nature of the Influenza A virus and its ability to induce high rates of mortality are ever more pertinent. Recently a novel protein encoded by an alternate reading frame in the PB1 Gene segment of Influenza A virus has been discovered and in turn shown to enhance viral virulence in a mouse model [1]. This protein has been shown to specifically target and destroy alveolar macrophages [2]. This review suggests that this protein, present in all previous pandemic strains, may reappear as a virulence factor in a subsequent pandemic strain. This PB1-F2 protein will enhance the mortality rate of the virus by increasing the likelihood of a secondary bacterial infection, which is the primary cause of death to a patient infected with Influenza A.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Chen W: A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001,7(12):1306-12. 10.1038/nm1201-1306PubMedCrossRef Chen W: A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001,7(12):1306-12. 10.1038/nm1201-1306PubMedCrossRef
4.
go back to reference Neznanov N, et al.: Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. J Biol Chem 280(25):24153-8. 2005 Jun 24; Epub 2005 Apr 21 10.1074/jbc.M502303200 Neznanov N, et al.: Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. J Biol Chem 280(25):24153-8. 2005 Jun 24; Epub 2005 Apr 21 10.1074/jbc.M502303200
5.
go back to reference Salvatore M, et al.: Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol 2002,76(3):1206-12.PubMedPubMedCentralCrossRef Salvatore M, et al.: Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol 2002,76(3):1206-12.PubMedPubMedCentralCrossRef
6.
go back to reference Steinhauer DA, et al.: Genetics of influenza virus. Annu Rev Genet 2002, 36: 305-332. 10.1146/annurev.genet.36.052402.152757PubMedCrossRef Steinhauer DA, et al.: Genetics of influenza virus. Annu Rev Genet 2002, 36: 305-332. 10.1146/annurev.genet.36.052402.152757PubMedCrossRef
7.
go back to reference Russell CJ, et al.: The genesis of a pandemic influenza virus. Cell 2005, 123: 368-371. 10.1016/j.cell.2005.10.019PubMedCrossRef Russell CJ, et al.: The genesis of a pandemic influenza virus. Cell 2005, 123: 368-371. 10.1016/j.cell.2005.10.019PubMedCrossRef
8.
go back to reference Zamarin D, et al.: Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog 2005,1(1):e4. Epub 2005 Sep 30 10.1371/journal.ppat.0010004PubMedPubMedCentralCrossRef Zamarin D, et al.: Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog 2005,1(1):e4. Epub 2005 Sep 30 10.1371/journal.ppat.0010004PubMedPubMedCentralCrossRef
9.
go back to reference Sethi S: Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics 2002,57(3):56-61.PubMed Sethi S: Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics 2002,57(3):56-61.PubMed
11.
go back to reference Thompson WW, et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289: 179-186. 10.1001/jama.289.2.179PubMedCrossRef Thompson WW, et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289: 179-186. 10.1001/jama.289.2.179PubMedCrossRef
12.
go back to reference Cram P, et al.: Influenza: Cost of illness and considerations in the economic evaluation of new and emerging therapies. Pharmacoeconomics 2001, 19: 223-230. 10.2165/00019053-200119030-00001PubMedCrossRef Cram P, et al.: Influenza: Cost of illness and considerations in the economic evaluation of new and emerging therapies. Pharmacoeconomics 2001, 19: 223-230. 10.2165/00019053-200119030-00001PubMedCrossRef
13.
go back to reference Neuman G, et al.: Orthomyxovirus replication, transcription, and polyadenylation. Curr Top Microbiol Immunol 2004, 283: 121-43. Neuman G, et al.: Orthomyxovirus replication, transcription, and polyadenylation. Curr Top Microbiol Immunol 2004, 283: 121-43.
14.
go back to reference Belay ED: Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 340(18):1377-82. 1999 May 6; 10.1056/NEJM199905063401801 Belay ED: Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 340(18):1377-82. 1999 May 6; 10.1056/NEJM199905063401801
15.
go back to reference Bergen GA, et al.: Influenza. More than mom and chicken soup. J Fla Med Assoc 1996,83(1):19-22.PubMed Bergen GA, et al.: Influenza. More than mom and chicken soup. J Fla Med Assoc 1996,83(1):19-22.PubMed
16.
go back to reference Chilvers MA: Local mucociliary defence mechanisms. Paediatr Respir Rev 2000,1(1):27-34. 10.1053/prrv.2000.0009PubMed Chilvers MA: Local mucociliary defence mechanisms. Paediatr Respir Rev 2000,1(1):27-34. 10.1053/prrv.2000.0009PubMed
17.
18.
19.
go back to reference Sibille Y, et al.: Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990, 141: 471-501.PubMedCrossRef Sibille Y, et al.: Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990, 141: 471-501.PubMedCrossRef
20.
go back to reference Martin TR: Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol 2000, 23: 128-132.PubMedCrossRef Martin TR: Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol 2000, 23: 128-132.PubMedCrossRef
21.
go back to reference Medzhitov R, et al.: Decoding the Patterns of Self and Nonself by the Innate Immune System. Science 296(5566):298-300. 12 April 2002 10.1126/science.1068883 Medzhitov R, et al.: Decoding the Patterns of Self and Nonself by the Innate Immune System. Science 296(5566):298-300. 12 April 2002 10.1126/science.1068883
22.
go back to reference Goldsby R, et al.: Kuby Immunology Cp2. 4th edition. W.H. Freeman And Company, New York; 2001:27. Goldsby R, et al.: Kuby Immunology Cp2. 4th edition. W.H. Freeman And Company, New York; 2001:27.
23.
24.
go back to reference Jackson RJ: Alternative mechanisms of initiating translation of mammalian mRNAs. Biochem Soc Trans 2005,33(Pt 6):1231-41.PubMedCrossRef Jackson RJ: Alternative mechanisms of initiating translation of mammalian mRNAs. Biochem Soc Trans 2005,33(Pt 6):1231-41.PubMedCrossRef
25.
go back to reference Gibbs JS: The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J Virol 2003,77(13):7214-24. 10.1128/JVI.77.13.7214-7224.2003PubMedPubMedCentralCrossRef Gibbs JS: The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J Virol 2003,77(13):7214-24. 10.1128/JVI.77.13.7214-7224.2003PubMedPubMedCentralCrossRef
26.
go back to reference Yamada H, et al.: Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria. FEBs Lett 578(3):331-6. 2004 Dec 17 10.1016/j.febslet.2004.11.017 Yamada H, et al.: Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria. FEBs Lett 578(3):331-6. 2004 Dec 17 10.1016/j.febslet.2004.11.017
27.
go back to reference Chanturiya N: PB1-F2, an influenza A virus-encoded proapoptotic mitochondrial protein, creates variably sized pores in planar lipid membranes. J Virol 2004,78(12):6304-12. 10.1128/JVI.78.12.6304-6312.2004PubMedPubMedCentralCrossRef Chanturiya N: PB1-F2, an influenza A virus-encoded proapoptotic mitochondrial protein, creates variably sized pores in planar lipid membranes. J Virol 2004,78(12):6304-12. 10.1128/JVI.78.12.6304-6312.2004PubMedPubMedCentralCrossRef
28.
go back to reference Obenauer JC, et al.: Large-scale sequence analysis of avian influenza isolates. 311(5767):1576-80. 2006 Mar 17 Epub 2006 Jan 26 Obenauer JC, et al.: Large-scale sequence analysis of avian influenza isolates. 311(5767):1576-80. 2006 Mar 17 Epub 2006 Jan 26
29.
go back to reference World Health Organization, Epidemic and Pandemic Alert and Response (EPR) Avian Influenza 5 December 2005 World Health Organization, Epidemic and Pandemic Alert and Response (EPR) Avian Influenza 5 December 2005
Metadata
Title
The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages
Author
J Robert Coleman
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-9

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine